Celgene Needs a Boost, But Juno Therapeutics Isn't It

Bookmark
(Bloomberg Gadfly) -- Celgene Corp. apparently heard investor complaints about the paltry size of its last deal.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.